Submucosal Bevacizumab ( DrugBank: Bevacizumab )


1 disease
IDDisease name (Link within this page)Number of trials
227Osler disease3

227. Osler disease


Clinical trials : 54 Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01314274
(ClinicalTrials.gov)
March 20119/3/2011Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic TelangiectasiaHHT;Morbus Osler;EpistaxisDrug: Bevacizumab;Drug: NaClMedical University of ViennaNULLCompleted18 Years80 YearsBoth15Phase 2Austria
2EUCTR2009-018049-19-AT
(EUCTR)
13/12/201023/11/2010A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHTA randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT epistaxisTrade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung
INN or Proposed INN: BEVACIZUMAB
Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Other descriptive name: SODIUM CHLORIDE
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und OhrenkrankheitenNULLNot RecruitingFemale: yes
Male: yes
30Austria
3NCT01402531
(ClinicalTrials.gov)
July 22, 201019/7/2011Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: Submucosal BevacizumabUniversity of California, San DiegoNULLCompleted18 YearsN/AAll10Phase 2United States